

# Francisco Sanchez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6604276/publications.pdf>

Version: 2024-02-01

14  
papers

176  
citations

1307594

7  
h-index

1199594

12  
g-index

15  
all docs

15  
docs citations

15  
times ranked

337  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | The Mitochondrial Complex I Activity Is Reduced in Cells with Impaired Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Function. PLoS ONE, 2012, 7, e48059.  | 2.5 | 40        |
| 2  | Alpha Lipoic Acid: A Therapeutic Strategy that Tend to Limit the Action of Free Radicals in Transplantation. International Journal of Molecular Sciences, 2018, 19, 102.  | 4.1 | 27        |
| 3  | Transient Cholesterol Effects on Nicotinic Acetylcholine Receptor Cell-Surface Mobility. PLoS ONE, 2014, 9, e100346.  | 2.5 | 26        |
| 4  | Thalamus volume change and cognitive impairment in early relapsing&acirc;remitting multiple sclerosis patients. Neuroradiology Journal, 2018, 31, 350-355.  | 1.2 | 19        |
| 5  | Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy. Current Clinical Pharmacology, 2019, 14, 91-100.  | 0.6 | 16        |
| 6  | Validation of CSF free light chain in diagnosis and prognosis of multiple sclerosis and clinically isolated syndrome: prospective cohort study in Buenos Aires. Journal of Neurology, 2019, 266, 112-118.   | 3.6 | 12        |
| 7  | Structural sex differences at disease onset in multiple sclerosis patients. Neuroradiology Journal, 2016, 29, 368-371.  | 1.2 | 11        |
| 8  | Real-World Effectiveness and Safety of Fingolimod in Patients With Relapsing Remitting Multiple Sclerosis: A Prospective Analysis in Buenos Aires, Argentina. Clinical Neuropharmacology, 2019, 42, 163-166.  | 0.7 | 6         |
| 9  | SLPI in the perfusion solution helps to identify graft quality in kidney transplants. Biomarkers in Medicine, 2019, 13, 895-906.  | 1.4 | 5         |
| 10 | Do clinical trials for new disease modifying treatments include real world patients with multiple sclerosis?. Multiple Sclerosis and Related Disorders, 2020, 39, 101931.   | 2.0 | 5         |
| 11 | New MRI lesions and topography at 6 months of treatment initiation and disease activity during follow up in relapsing remitting multiple sclerosis patients. Neurological Research, 2020, 42, 148-152.  | 1.3 | 5         |
| 12 | Brain magnetic resonance imaging features in multiple sclerosis and neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody in a Latin American population. Multiple Sclerosis and Related Disorders, 2020, 42, 102049. | 2.0 | 4         |
| 13 | Differential white and gray matter damage in highly active multiple sclerosis: A prospective cohort study. Journal of Clinical Neuroscience, 2020, 74, 65-68.   | 1.5 | 0         |
| 14 | SLPI (secretory leukocyte peptidase inhibitor). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2017, , .   | 0.1 | 0         |